



# Summary of MS treatments

More detail on each of these medications can be found in our **medications factsheets** that summarise the key information, including potential side effects, to provide you with background information that you can then discuss with your healthcare providers.

	Disease Modifying Therapies (DMTs)											Symptomatic Therapies				
	oral tablet				injection					infusion						
<b>Brand name</b>	<b>Aubagio®</b>	<b>Gilenya®</b>	<b>MAVENCLAD®</b>	<b>Tecfidera®</b>	<b>Avonex®</b>	<b>Betaferon®</b>	<b>Copaxone®</b>	<b>Plegridy®</b>	<b>Rebif®</b>	<b>Lemtrada®</b>	<b>Ocrevus®</b>	<b>Tysabri®</b>	<b>Botox®</b>	<b>Fampyra®</b>	<b>Sativex®</b>	
<b>Generic name</b>	teriflunomide	fingolimod	cladribine tablets	dimethyl fumarate	interferon b-1a	interferon b-1b	glatiramer acetate	interferon b-1a (pegylated)	interferon b-1a	alemtuzumab	ocrelizumab	natalizumab	botulinum toxin type A	fampridine	nabiximols	
<b>Manufacturer</b>	Sanofi Genzyme	Novartis Australia	Merck	Biogen	Biogen	Bayer Australia	Teva	Biogen	Merck Serono	Sanofi Genzyme	Roche	Biogen	Allergan	Biogen	Emerge Health Pty Ltd	
<b>Indications (forms of MS that the treatment is used for)</b>	Relapsing remitting MS (RRMS)	RRMS and relapses in patients with secondary progressive MS (SPMS)	RRMS	RRMS	RRMS	Single clinical event indicating high risk of MS, RRMS, SPMS	Single clinical event indicating high risk of MS & RRMS	RRMS	Single clinical event indicating high risk of MS & RRMS	RRMS	RRMS & Primary Progressive MS (PPMS)	RRMS	Any form of MS; for treatment of urinary incontinence	Any form of MS; to improve walking	Muscle stiffness (spasticity)	
<b>Route</b>	oral tablet	oral tablet	oral tablet	oral capsule	intramuscular injection	subcutaneous injection	subcutaneous injection	subcutaneous injection	subcutaneous injection	intravenous infusion	intravenous infusion	intravenous infusion	intramuscular injection	oral tablet	oromucosal (mouth) spray	
<b>Frequency</b>	one 14 mg tablet per day	one 0.5 mg tablet per day	Two treatment courses over two years; each treatment course consists of two weeks.	one 120mg capsule twice daily, increasing to 240g twice daily	once per week	every two days	40 mg, three times per week OR 20 mg daily (20 mg dose not available after 1-7-19)	every two weeks	three times per week	two treatment courses, 1 year apart	6 monthly; first treatment is split into 2 doses a fortnight apart	every 28 days	single treatment	Two tablets per day, 12 hours apart	A number of sprays per day depending on individual circumstances	
<b>Preparation</b>	film coated oral tablet	gel capsules	uncoated tablets	capsule	pre-filled syringe	pre-filled syringe	pre-filled syringe	single-use, pre-filled injection pens	pre-filled cartridge	prepared by pharmacy or clinic staff	prepared by pharmacy or clinic staff	prepared by pharmacy or clinic staff	multiple injections by doctor during one visit	film coated oral tablet	10mL glass spray container and a pump	
<b>Storage</b>	room temperature, below 30°C	room temperature, below 30°C	room temperature, below 25°C	room temperature, below 30°C	refrigerate 2-8°C	room temperature, below 25°C	refrigerate 2-8°C	refrigerate 2-8°C	refrigerate 2-8°C	stored in the pharmacy or clinic at 2-8°C	stored in the pharmacy or clinic at 2-8°C	stored in the pharmacy or clinic at 2-8°C	doctor will arrange storage	room temperature, below 25°C	refrigerate 2-8°C	
<b>Available on PBS</b>	Yes	Yes	Yes (from 1 Jan 2019)	Yes	Yes	Yes, RRMS only, not for single clinical event	Yes, RRMS only, not for single clinical event. 20 mg dose deleted from PBS from 1-7-19	Yes	Yes, RRMS only, not for single clinical event	Yes	RRMS Yes PPMS No	Yes	Yes	No	No	No